Literature DB >> 22850422

Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells.

Curdin Conrad1, Josh Gregorio, Yi-Hong Wang, Tomoki Ito, Stephan Meller, Shino Hanabuchi, Sonya Anderson, Neely Atkinson, Pedro T Ramirez, Yong-Jun Liu, Ralph Freedman, Michel Gilliet.   

Abstract

Epithelial ovarian cancer (EOC) is the fifth most common cause of cancer death among women. Despite its immunogenicity, effective antitumor responses are limited, due, in part, to the presence of forkhead box protein 3-positive (Foxp3(+)) T regulatory (Treg) cells in the tumor microenvironment. However, the mechanisms that regulate the accumulation and the suppressive function of these Foxp3(+) Treg cells are poorly understood. Here, we found that the majority of Foxp3(+) Treg cells accumulating in the tumor microenvironment of EOCs belong to the subset of Foxp3(+) Treg cells expressing inducible costimulator (ICOS). The expansion and the suppressive function of these cells were strictly dependent on ICOS-L costimulation provided by tumor plasmacytoid dendritic cells (pDC). Accordingly, ICOS(+) Foxp3(+) Treg cells were found to localize in close vicinity of tumor pDCs, and their number directly correlated with the numbers of pDCs in the tumors. Furthermore, pDCs and ICOS(+) Foxp3(+) Treg cells were found to be strong predictors for disease progression in patients with ovarian cancer, with ICOS(+) Treg cell subset being a stronger predictor than total Foxp3(+) Treg cells. These findings suggest an essential role for pDCs and ICOS-L in immunosuppression mediated by ICOS(+) Foxp3(+) Treg cells, leading to tumor progression in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22850422      PMCID: PMC3652570          DOI: 10.1158/0008-5472.CAN-12-2271

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts.

Authors:  Jordi C Ochando; Chiho Homma; Yu Yang; Andres Hidalgo; Alexandre Garin; Frank Tacke; Veronique Angeli; Yansui Li; Peter Boros; Yaozhong Ding; Rolf Jessberger; Giorgio Trinchieri; Sergio A Lira; Gwendalyn J Randolph; Jonathan S Bromberg
Journal:  Nat Immunol       Date:  2006-04-23       Impact factor: 25.606

2.  Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.

Authors:  Junliang Fu; Dongping Xu; Zhenwen Liu; Ming Shi; Ping Zhao; Baoyun Fu; Zheng Zhang; Huiyin Yang; Hui Zhang; Chunbao Zhou; Jinxia Yao; Lei Jin; Huifen Wang; Yongping Yang; Yang-Xing Fu; Fu-Sheng Wang
Journal:  Gastroenterology       Date:  2007-04-14       Impact factor: 22.682

3.  Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.

Authors:  Hiroaki Kajiyama; Kiyosumi Shibata; Mikio Terauchi; Kazuhiko Ino; Akihiro Nawa; Fumitaka Kikkawa
Journal:  Int J Cancer       Date:  2008-01-01       Impact factor: 7.396

4.  The ICOS molecule plays a crucial role in the development of mucosal tolerance.

Authors:  Katsuichi Miyamoto; Cherry I Kingsley; Xingmin Zhang; Claudia Jabs; Leonid Izikson; Raymond A Sobel; Howard L Weiner; Vijay K Kuchroo; Arlene H Sharpe
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

5.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

Authors:  Eiichi Sato; Sara H Olson; Jiyoung Ahn; Brian Bundy; Hiroyoshi Nishikawa; Feng Qian; Achim A Jungbluth; Denise Frosina; Sacha Gnjatic; Christine Ambrosone; James Kepner; Tosin Odunsi; Gerd Ritter; Shashikant Lele; Yao-Tseng Chen; Haruo Ohtani; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

6.  Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage.

Authors:  Ivan Perrot; Dominique Blanchard; Nathalie Freymond; Sylvie Isaac; Benoît Guibert; Yves Pachéco; Serge Lebecque
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

7.  Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.

Authors:  Mirjana Urosevic; Reinhard Dummer; Curdin Conrad; Mirjam Beyeler; Elisabeth Laine; Günter Burg; Michel Gilliet
Journal:  J Natl Cancer Inst       Date:  2005-08-03       Impact factor: 13.506

Review 8.  The impact of T-cell immunity on ovarian cancer outcomes.

Authors:  Brad H Nelson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

9.  Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma.

Authors:  Maja A Hofmann; Christian Kors; Heike Audring; Peter Walden; Wolfram Sterry; Uwe Trefzer
Journal:  J Immunother       Date:  2008-06       Impact factor: 4.456

10.  Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand.

Authors:  Tomoki Ito; Maria Yang; Yui-Hsi Wang; Roberto Lande; Josh Gregorio; Olivia A Perng; Xiao-Feng Qin; Yong-Jun Liu; Michel Gilliet
Journal:  J Exp Med       Date:  2007-01-02       Impact factor: 14.307

View more
  110 in total

1.  Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg.

Authors:  Moanaro Biswas; Debalina Sarkar; Sandeep R P Kumar; Sushrusha Nayak; Geoffrey L Rogers; David M Markusic; Gongxian Liao; Cox Terhorst; Roland W Herzog
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 2.  FOXP3-Positive Regulatory T Cells and Kidney Allograft Tolerance.

Authors:  Alessandro Alessandrini; Laurence A Turka
Journal:  Am J Kidney Dis       Date:  2016-12-31       Impact factor: 8.860

Review 3.  A pathogenic role of plasmacytoid dendritic cells in autoimmunity and chronic viral infection.

Authors:  Franck J Barrat; Lishan Su
Journal:  J Exp Med       Date:  2019-08-16       Impact factor: 14.307

Review 4.  Aiming to immune elimination of ovarian cancer stem cells.

Authors:  Jiabo Di; Tjitske Duiveman-de Boer; Carl G Figdor; Ruurd Torensma
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

5.  A distinct subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes.

Authors:  Hong Zhang; Josh D Gregorio; Toru Iwahori; Xiangyue Zhang; Okmi Choi; Lorna L Tolentino; Tyler Prestwood; Yaron Carmi; Edgar G Engleman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-06       Impact factor: 11.205

Review 6.  Innate immune regulation by STAT-mediated transcriptional mechanisms.

Authors:  Haiyan S Li; Stephanie S Watowich
Journal:  Immunol Rev       Date:  2014-09       Impact factor: 12.988

7.  Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors.

Authors:  Alexander Pedroza-Gonzalez; Guoying Zhou; Ernesto Vargas-Mendez; Patrick Pc Boor; Shanta Mancham; Cornelis Verhoef; Wojciech G Polak; Dirk Grünhagen; Qiuwei Pan; Harry LA Janssen; Gina S Garcia-Romo; Katharina Biermann; Eric Ttl Tjwa; Jan Nm IJzermans; Jaap Kwekkeboom; Dave Sprengers
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

8.  IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.

Authors:  Geok Choo Sim; Natalia Martin-Orozco; Lei Jin; Yan Yang; Sheng Wu; Edwina Washington; Deborah Sanders; Carol Lacey; Yijun Wang; Luis Vence; Patrick Hwu; Laszlo Radvanyi
Journal:  J Clin Invest       Date:  2014-01       Impact factor: 14.808

9.  Transient decrease in human peripheral blood myeloid dendritic cells following influenza vaccination correlates with induction of serum antibody.

Authors:  James J Kobie; John J Treanor; Christopher T Ritchlin
Journal:  Immunol Invest       Date:  2014       Impact factor: 3.657

10.  Engineering nanomaterials to address cell-mediated inflammation in atherosclerosis.

Authors:  Sean Allen; Yu-Gang Liu; Evan Scott
Journal:  Regen Eng Transl Med       Date:  2016-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.